These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
314 related articles for article (PubMed ID: 32476236)
1. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Facchin S; Vitulo N; Calgaro M; Buda A; Romualdi C; Pohl D; Perini B; Lorenzon G; Marinelli C; D'Incà R; Sturniolo GC; Savarino EV Neurogastroenterol Motil; 2020 Oct; 32(10):e13914. PubMed ID: 32476236 [TBL] [Abstract][Full Text] [Related]
2. Inulin-type fructans improve active ulcerative colitis associated with microbiota changes and increased short-chain fatty acids levels. Valcheva R; Koleva P; Martínez I; Walter J; Gänzle MG; Dieleman LA Gut Microbes; 2019; 10(3):334-357. PubMed ID: 30395776 [TBL] [Abstract][Full Text] [Related]
3. Dark-purple rice extract modulates gut microbiota composition in acetic acid- and indomethacin-induced inflammatory bowel disease in rats. Thipart K; Gruneck L; Phunikhom K; Sharpton TJ; Sattayasai J; Popluechai S Int Microbiol; 2023 May; 26(2):423-434. PubMed ID: 36484910 [TBL] [Abstract][Full Text] [Related]
4. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413 [TBL] [Abstract][Full Text] [Related]
5. Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis. Laserna-Mendieta EJ; Clooney AG; Carretero-Gomez JF; Moran C; Sheehan D; Nolan JA; Hill C; Gahan CGM; Joyce SA; Shanahan F; Claesson MJ J Crohns Colitis; 2018 Jan; 12(2):204-216. PubMed ID: 29373727 [TBL] [Abstract][Full Text] [Related]
6. Effects of short-chain fatty acid-butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. Firoozi D; Masoumi SJ; Mohammad-Kazem Hosseini Asl S; Labbe A; Razeghian-Jahromi I; Fararouei M; Lankarani KB; Dara M Lipids Health Dis; 2024 Jul; 23(1):216. PubMed ID: 39003477 [TBL] [Abstract][Full Text] [Related]
7. Response of gastrointestinal fermentative activity and colonic microbiota to protected sodium butyrate and protected sodium heptanoate in weaned piglets challenged with ETEC F4 López-Colom P; Castillejos L; Barba-Vidal E; Zhu Y; Puyalto M; Mallo JJ; Martín-Orúe SM Arch Anim Nutr; 2019 Oct; 73(5):339-359. PubMed ID: 31342760 [TBL] [Abstract][Full Text] [Related]
8. Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes". Facchin S; Buda A; Savarino E Neurogastroenterol Motil; 2021 Jan; 33(1):e14054. PubMed ID: 33274806 [No Abstract] [Full Text] [Related]
9. Effects of soy milk consumption on gut microbiota, inflammatory markers, and disease severity in patients with ulcerative colitis: a study protocol for a randomized clinical trial. Sadeghi O; Milajerdi A; Siadat SD; Keshavarz SA; Sima AR; Vahedi H; Adibi P; Esmaillzadeh A Trials; 2020 Jun; 21(1):565. PubMed ID: 32576228 [TBL] [Abstract][Full Text] [Related]
10. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease. Imhann F; Vich Vila A; Bonder MJ; Fu J; Gevers D; Visschedijk MC; Spekhorst LM; Alberts R; Franke L; van Dullemen HM; Ter Steege RWF; Huttenhower C; Dijkstra G; Xavier RJ; Festen EAM; Wijmenga C; Zhernakova A; Weersma RK Gut; 2018 Jan; 67(1):108-119. PubMed ID: 27802154 [TBL] [Abstract][Full Text] [Related]
11. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial. Cox SR; Lindsay JO; Fromentin S; Stagg AJ; McCarthy NE; Galleron N; Ibraim SB; Roume H; Levenez F; Pons N; Maziers N; Lomer MC; Ehrlich SD; Irving PM; Whelan K Gastroenterology; 2020 Jan; 158(1):176-188.e7. PubMed ID: 31586453 [TBL] [Abstract][Full Text] [Related]
12. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease. Li G; Lin J; Zhang C; Gao H; Lu H; Gao X; Zhu R; Li Z; Li M; Liu Z Gut Microbes; 2021; 13(1):1968257. PubMed ID: 34494943 [TBL] [Abstract][Full Text] [Related]
13. Gut microbiota differs between children with Inflammatory Bowel Disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis. Knoll RL; Forslund K; Kultima JR; Meyer CU; Kullmer U; Sunagawa S; Bork P; Gehring S Am J Physiol Gastrointest Liver Physiol; 2017 Apr; 312(4):G327-G339. PubMed ID: 28039159 [TBL] [Abstract][Full Text] [Related]
14. Prebiotic UG1601 mitigates constipation-related events in association with gut microbiota: A randomized placebo-controlled intervention study. Chu JR; Kang SY; Kim SE; Lee SJ; Lee YC; Sung MK World J Gastroenterol; 2019 Oct; 25(40):6129-6144. PubMed ID: 31686768 [TBL] [Abstract][Full Text] [Related]
15. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review. Recharla N; Geesala R; Shi XZ Nutrients; 2023 May; 15(10):. PubMed ID: 37242159 [No Abstract] [Full Text] [Related]
16. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: a randomised controlled trial. de Groot PF; Nikolic T; Imangaliyev S; Bekkering S; Duinkerken G; Keij FM; Herrema H; Winkelmeijer M; Kroon J; Levin E; Hutten B; Kemper EM; Simsek S; Levels JHM; van Hoorn FA; Bindraban R; Berkvens A; Dallinga-Thie GM; Davids M; Holleman F; Hoekstra JBL; Stroes ESG; Netea M; van Raalte DH; Roep BO; Nieuwdorp M Diabetologia; 2020 Mar; 63(3):597-610. PubMed ID: 31915895 [TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-analysis: Short-Chain Fatty Acid Characterization in Patients With Inflammatory Bowel Disease. Zhuang X; Li T; Li M; Huang S; Qiu Y; Feng R; Zhang S; Chen M; Xiong L; Zeng Z Inflamm Bowel Dis; 2019 Oct; 25(11):1751-1763. PubMed ID: 31498864 [TBL] [Abstract][Full Text] [Related]
18. Gut microbiota in the pathogenesis of inflammatory bowel disease. Nishida A; Inoue R; Inatomi O; Bamba S; Naito Y; Andoh A Clin J Gastroenterol; 2018 Feb; 11(1):1-10. PubMed ID: 29285689 [TBL] [Abstract][Full Text] [Related]
19. Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review. Wang C; Gu Y; Chu Q; Wang X; Ding Y; Qin X; Liu T; Wang S; Liu X; Wang B; Cao H Microbiol Res; 2024 May; 282():127660. PubMed ID: 38442454 [TBL] [Abstract][Full Text] [Related]
20. Effect of cinnamon essential oil on gut microbiota in the mouse model of dextran sodium sulfate-induced colitis. Li AL; Ni WW; Zhang QM; Li Y; Zhang X; Wu HY; Du P; Hou JC; Zhang Y Microbiol Immunol; 2020 Jan; 64(1):23-32. PubMed ID: 31595527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]